Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Carboplatin and Bevacizumab for Recurrent Ependymoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
ClinicalTrials.gov Identifier:
NCT01295944
First received: February 11, 2011
Last updated: September 21, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2020
  Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)